Clinical study of DC-CIK cell combined with chemotherapy in the treatment of advanced non-small cell lung cancer
10.7619/jcmp.201715023
- VernacularTitle:DC-CIK细胞联合化疗治疗晚期非小细胞肺癌的临床研究
- Author:
Zhishang WANG
1
;
Xiemin FENG
;
Dongdong TIAN
Author Information
1. 延安大学附属医院
- Keywords:
DC-CIK;
advanced non-small cell lung cancer;
clinical efficacy
- From:
Journal of Clinical Medicine in Practice
2017;21(15):85-87,91
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and clinical efficacy of DC-CIK cell combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).Methods A total of 112 patients with NSCLC were randomly divided into observation group (n=56) and control group (n=56), the observation group was treated with DC-CIK immunotherapy combined with chemotherapy, and the control group was treated with chemotherapy only, then the efficacy and safety were compared between the two groups.Results The response rate of the observation group and the control group were 60.7% and 48.9%, respectively, and there was no significantly difference(P>0.05), and the disease control rate of the observation group was 89.3%, which was higher than 73.2% in the control group(P<0.05).The KPS score in the observation group after treatment was significantly higher than that in the control group (P<0.05).Compared with the control group, the observation group had less toxicity reaction, and longer middle survival time (P<0.05).Conclusion DC-CIK cell combined with chemotherapy can effectively increase the disease control rate, extend the survival time, and improve the quality of life in patients with NSCLC, so it is worthy of promotion.
